JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1997; 29:1284-1289
© 1997 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malik, P
Right arrow Articles by Sheldon, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malik, P
Right arrow Articles by Sheldon, R

Timing of first recurrence of syncope predicts syncopal frequency after a positive tilt table test result

P Malik, ML Koshman, and R Sheldon

Cardiovascular Research Group, University of Calgary, Alberta, Canada.

OBJECTIVES: This study sought to determine whether the time to first recurrence of syncope after a positive isoproteremol-tilt table test result accurately predicts the eventual frequency of syncope. BACKGROUND: Both patient care and future clinical trials involving patients with neuromediated syncope will require a simple measure that reflects the frequency of syncope. The time from tilt table testing to the first recurrence of syncope might be such a measure. METHODS: A cohort of 46 patients with syncope, in a university outpatient clinic, who had at least one syncopal spell after a positive isoproterenol-tilt table test result were followed up for up to 6.5 years (mean [+/-SD] 48 +/- 14 months). The time from tilt table testing to the first recurrence of syncope was correlated. RESULTS: A total of 40 of 46 patients had more than one recurrent spell, with a median of eight recurrent spells. The time to the first syncopal spell predicted the frequency of spells with r = -0.79 (p < 0.001), whereas the time to the second spell predicted the frequency with r = -0.92 (p < 0.001). Patients who fainted within 1 month of tilt testing had a geometric mean frequency of 1.35 spells/month (95% confidence limits 0.49, 3.74) compared with patients who fainted 1 to 24 months after testing (0.12 spells/months; 95% confidence limits 0.07 to 0.18, p < 0.001). Finally, the frequency of syncopal spells bore no relation to the duration of follow-up. CONCLUSIONS: The time to the first recurrent spell predicts the frequency of syncopal spells after a positive tilt table test result, and the instantaneous risk of syncope is constant.


This article has been cited by other articles:


Home page
CirculationHome page
R. Sheldon, S. Connolly, S. Rose, T. Klingenheben, A. Krahn, C. Morillo, M. Talajic, T. Ku, F. Fouad-Tarazi, D. Ritchie, et al.
Prevention of Syncope Trial (POST): A Randomized, Placebo-Controlled Study of Metoprolol in the Prevention of Vasovagal Syncope
Circulation, March 7, 2006; 113(9): 1164 - 1170.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. Raviele, F. Giada, C. Menozzi, G. Speca, S. Orazi, G. Gasparini, R. Sutton, M. Brignole, and for the Vasovagal Syncope and Pacing Trial Investi
A randomized, double-blind, placebo-controlled study of permanent cardiac pacing for the treatment of recurrent tilt-induced vasovagal syncope. The vasovagal syncope and pacing trial (SYNPACE)
Eur. Heart J., October 1, 2004; 25(19): 1741 - 1748.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
R. Sheldon, S. Rose, S. Connolly, and on behalf of the POST investigators
Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope: Rationale and study design
Europace, January 1, 2003; 5(1): 71 - 75.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
R. S. Sheldon, S. R. Raj, S. Rose, and S. J. Connolly
Beta-blockers in syncope: the jury is still out
J. Am. Coll. Cardiol., December 1, 2001; 38(7): 2135 - 2135.
[Full Text] [PDF]


Home page
CirculationHome page
F. Ammirati, F. Colivicchi, and M. Santini
Permanent Cardiac Pacing Versus Medical Treatment for the Prevention of Recurrent Vasovagal Syncope : A Multicenter, Randomized, Controlled Trial
Circulation, July 3, 2001; 104(1): 52 - 57.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
R. Sheldon and S. Rose
Components of clinical trials for vasovagal syncope
Europace, January 1, 2001; 3(3): 233 - 240.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
S. J. Connolly, R. Sheldon, R. S. Roberts, M. Gent, and on Behalf of the Vasovagal Pacemaker Study Investi
The North American vasovagal pacemaker study (VPS) : A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope
J. Am. Coll. Cardiol., January 1, 1999; 33(1): 16 - 20.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1997 by the American College of Cardiology Foundation.